The  ||| S:0 E:4 ||| DT
roles  ||| S:4 E:10 ||| NNS
of  ||| S:10 E:13 ||| IN
epidermal  ||| S:13 E:23 ||| JJ
growth  ||| S:23 E:30 ||| NN
factor  ||| S:30 E:37 ||| NN
receptor  ||| S:37 E:46 ||| NN
( ||| S:46 E:47 ||| -LRB-
EGFR ||| S:47 E:51 ||| NNP
)  ||| S:51 E:53 ||| -RRB-
inhibitors  ||| S:53 E:64 ||| NN
in  ||| S:64 E:67 ||| IN
the  ||| S:67 E:71 ||| DT
management  ||| S:71 E:82 ||| NN
of  ||| S:82 E:85 ||| IN
lung  ||| S:85 E:90 ||| NN
cancer  ||| S:90 E:97 ||| NN
Targeting  ||| S:97 E:107 ||| NNP
epidermal  ||| S:107 E:117 ||| JJ
growth  ||| S:117 E:124 ||| NN
factor  ||| S:124 E:131 ||| NN
receptor  ||| S:131 E:140 ||| NN
( ||| S:140 E:141 ||| -LRB-
EGFR ||| S:141 E:145 ||| NNP
)  ||| S:145 E:147 ||| -RRB-
is  ||| S:147 E:150 ||| VBZ
an  ||| S:150 E:153 ||| DT
important  ||| S:153 E:163 ||| JJ
treatment  ||| S:163 E:173 ||| NN
option  ||| S:173 E:180 ||| NN
for  ||| S:180 E:184 ||| IN
non-small  ||| S:184 E:194 ||| JJ
cell  ||| S:194 E:199 ||| NN
lung  ||| S:199 E:204 ||| NN
cancer  ||| S:204 E:211 ||| NN
( ||| S:211 E:212 ||| -LRB-
NSCLC ||| S:212 E:217 ||| NNP
) ||| S:217 E:218 ||| -RRB-
.  ||| S:218 E:220 ||| .
These  ||| S:220 E:226 ||| DT
targeted  ||| S:226 E:235 ||| JJ
therapies  ||| S:235 E:245 ||| NNS
have  ||| S:245 E:250 ||| VBP
been  ||| S:250 E:255 ||| VBN
studied  ||| S:255 E:263 ||| VBN
extensively  ||| S:263 E:275 ||| RB
in  ||| S:275 E:278 ||| IN
NSCLC  ||| S:278 E:284 ||| NNP
in  ||| S:284 E:287 ||| IN
first  ||| S:287 E:293 ||| JJ
line  ||| S:293 E:298 ||| NN
and  ||| S:298 E:302 ||| CC
subsequent  ||| S:302 E:313 ||| JJ
lines ||| S:313 E:318 ||| NNS
,  ||| S:318 E:320 ||| ,
including  ||| S:320 E:330 ||| VBG
maintenance  ||| S:330 E:342 ||| NN
in  ||| S:342 E:345 ||| IN
empiric  ||| S:345 E:353 ||| JJ
fashion  ||| S:353 E:361 ||| NN
or  ||| S:361 E:364 ||| CC
in  ||| S:364 E:367 ||| IN
patients  ||| S:367 E:376 ||| NNS
with  ||| S:376 E:381 ||| IN
tumors  ||| S:381 E:388 ||| NNS
harboring  ||| S:388 E:398 ||| VBG
the  ||| S:398 E:402 ||| DT
EGFR  ||| S:402 E:407 ||| NNP
mutations ||| S:407 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
In  ||| S:418 E:421 ||| IN
this  ||| S:421 E:426 ||| DT
manuscript ||| S:426 E:436 ||| NN
,  ||| S:436 E:438 ||| ,
we  ||| S:438 E:441 ||| PRP
will  ||| S:441 E:446 ||| MD
review  ||| S:446 E:453 ||| VB
in  ||| S:453 E:456 ||| IN
details  ||| S:456 E:464 ||| NNS
the  ||| S:464 E:468 ||| DT
evolutions  ||| S:468 E:479 ||| NN
of  ||| S:479 E:482 ||| IN
these  ||| S:482 E:488 ||| DT
targeted  ||| S:488 E:497 ||| JJ
therapy  ||| S:497 E:505 ||| NN
in  ||| S:505 E:508 ||| IN
the  ||| S:508 E:512 ||| DT
management  ||| S:512 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
NSCLC ||| S:526 E:531 ||| NNP
.  ||| S:531 E:533 ||| .
